How to cope with the quest for new antibiotics

FEBS Letters

Volumn 585, Issue 11, 2011, Pages 1673-1681

  Fabbretti, Attilio ^a   Gualerzi, Claudio O ^a   Brandi, Letizia ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Natural product; Rational design; Target based screening; Translational inhibitor; Underexploited target; Whole cell screening

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AN 3365; ANTIBIOTIC AGENT; BEDAQUILINE; BETA LACTAM ANTIBIOTIC; CHIR 090; DALBAVANCIN; DAPTOMYCIN; FIDAXOMICIN; FRIULIMICIN; GE 107558; GE 81112; GE 82832; GSK 299423; LINEZOLID; MIKAMYCIN B; MYXOPYRONIN; ORITAVANCIN; PLATENCIN; QPT 1; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RADEZOLID; STREPTOMYCIN; SULFANILAMIDE; TEICOPLANIN; TELAVANCIN; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VIRGINIAMYCIN; XF 73; ZEVEN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL CELL WALL; CELL SCREENING; CYTOTOXICITY; DRUG APPROVAL; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; GENE DUPLICATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; GRAM POSITIVE INFECTION; HIGH THROUGHPUT SCREENING; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RIBOSWITCH; RNA TRANSLATION; SKIN INFECTION; TRANSLATION INITIATION; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG DISCOVERY; HUMANS; PROTEIN BIOSYNTHESIS;

EID: 79957560165     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2011.04.029     Document Type: Review

References (73)

1. U. von Ahsen, J. Davies, and R. Schroeder Antibiotic inhibition of group I ribozyme function Nature 353 1991 368 370 (Pubitemid 21912514)
2. J. Davies, U. von Ahsen, and R. Schroeder Antibiotics and the RNA world: a role of low molecular weight effectors in biochemical evolution R.F. Gesteland, J.F. Atkins, The RNA World 1993 Cold Spring Harbor Laboratory Press Plainview, NY 185 204
3. M.A. Fischbach, and C.T. Walsh Antibiotics for emerging pathogens Science 325 2009 1089 1093
4. H. Broetz-Oesterhelt, and P. Sass Postgenomic strategies in antibacterial drug discovery Future Microbiol. 5 2010 1553 1579
5. S.J. Projan Why is big pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6 2003 427 430 (Pubitemid 37345405)
6. J.F. Barrett Can biotech deliver new antibiotics? Curr. Opin. Microbiol. 8 2005 498 503 (Pubitemid 41355028)
7. Infectious Diseases Society of America (2010). The 10×'20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 50, 1081-1083.
8. U. Theuretzbacher Future antibiotic scenarios: is the tide starting to turn? Int. J. Antimicrob. Agents 34 2009 15 20
9. D.J. Payne, M.N. Gwynn, D.J. Holmes, and D.L. Pompliano Drugs for bad bugs: confronting the challenges of antibacterial discovery Nat. Rev. Drug Discovery 6 2007 29 40 (Pubitemid 46020284)
10. S.C. Sukuru, J.L. Jenkins, R.E. Beckwith, J. Scheiber, A. Bender, D. Mikhailov, J.W. Davies, and M. Glick Plate-based diversity selection based on empirical HTS data to enhance the number of hits and their chemical diversity J. Biomol. Screen. 14 2009 690 699
11. K.S. Lam New aspects of natural products in drug discovery Trends Microbiol. 15 2007 279 289 (Pubitemid 46856162)
12. M.N. Gwynn, A. Portnoy, S.F. Rittenhouse, and D.J. Payne Challenges of antibacterial discovery revisited Ann. N. Y. Acad. Sci. 1213 2010 5 19
13. R.H. Baltz Antimicrobials from Actinomycetes: back to future Microbe 2 2007 125 131
14. S.B. Singh, J.W. Phillips, and J. Wang Highly sensitive target-based whole-cell antibacterial discovery strategy by antisense RNA silencing Curr. Opin. Drug Discov. Devel. 10 2007 160 166 (Pubitemid 46438645)
15. A. Urban, S. Eckermann, B. Fast, S. Metzger, M. Gehling, K. Ziegelbauer, H. Ruebsamen-Weigmann, and C. Freiberg Novel whole cell-antibiotic biosensors for compound discovery Appl. Environ. Microbiol. 73 2007 6436 6443 (Pubitemid 47623701)
16. J.L. Hobman, C.W. Penn, and M.J. Pallen Laboratory strains of Escherichia coli: model citizens or deceitful delinquents growing old disgracefully? Mol. Microbiol. 64 2007 881 885 (Pubitemid 46743964)
17. S.N. Richter, I. Frasson, M. Palumbo, C. Sissi, and G. Pal Simocyclinone D8 turns on against Gram-negative bacteria in a clinical setting Bioorg. Med. Chem. Lett. 20 2010 1202 1204
18. L. Brandi, A. Lazzarini, L. Cavaletti, M. Abbondi, E. Corti, I. Ciciliato, L. Gastaldo, A. Marazzi, M. Feroggio, A. Fabbretti, A. Maio, L. Colombo, S. Donadio, F. Marinelli, D. Losi, C.O. Gualerzi, and E. Selva Novel tetrapeptide inhibitors of bacterial protein synthesis produced by a Streptomyces sp. Biochemistry 45 2006 3692 3702
19. L. Brandi, A. Fabbretti, A. La Teana, M. Abbondi, D. Losi, S. Donadio, and C.O. Gualerzi Specific, efficient and selective inhibition of prokaryotic translation initiation by a novel peptide antibiotic Proc. Natl. Acad. Sci. USA 103 2006 39 44 (Pubitemid 43076101)
20. L. Brandi, A. Fabbretti, C.L. Pon, A.E. Dahlberg, and C.O. Gualerzi Initiation of protein synthesis: a target for antimicrobials Expert Opin. Ther. Targets 12 2008 519 534 (Pubitemid 351699474)
21. L. Brandi, A. Fabbretti, M. Di Stefano, A. Lazzarini, M. Abbondi, and C.O. Gualerzi Characterization of GE82832, a peptide inhibitor of translocation interacting with bacterial 30S ribosomal subunits RNA 12 2006 1262 1270 (Pubitemid 43990551)
22. Fabbretti, A. (2007). Real-time dynamics of ribosome-initiation factor interaction by time-resolved chemical probing. Ph.D. Thesis, University of Camerino.
23. L. Brandi, A. Fabbretti, P. Milon, M. Carotti, C.L. Pon, and C.O. Gualerzi Methods for identifying compounds that specifically target translation Methods Enzymol. 431 2007 229 267
24. L. Brandi, J. Dresios, and C.O. Gualerzi Assays for the identification of inhibitors targeting specific translational steps Methods Mol. Med. 142 2008 87 105
25. S. Donadio, S. Maffioli, P. Monciardini, M. Sosio, and D. Jabes Source of novel antibiotics - aside the common roads Appl. Microbiol. Biotechnol. 88 2010 1261 1267
26. I. Mochalkin, J.R. Miller, L. Narasimhan, V. Thanabal, P. Erdman, P.B. Cox, J.V. Prasad, S. Lightle, M.D. Huband, and C.K. Stover Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches ACS Chem. Biol. 4 2009 473 483
27. K.A. Rawls, P.T. Lang, J. Takeuchi, S. Imamura, T.D. Baguley, C. Grundner, T. Alber, and J.A. Ellman Fragment-based discovery of selective inhibitors of the Mycobacterium tuberculosis protein tyrosine phosphatase PtpA Bioorg. Med. Chem. Lett. 19 2009 6851 6854
28. C. Scheich, V. Puetter, and M. Schade Novel small molecule inhibitors of MDR Mycobacterium tuberculosis by NMR fragment screening of antigen 85C J. Med. Chem. 53 2010 8362 8367
29. T.A. Mukhtar, K.P. Koteva, and G.D. Wright Chimeric streptogramin- tyrocidine antibiotics that overcome streptogramin resistance Chem. Biol. 12 2005 229 235 (Pubitemid 40281330)
30. M.M. Butler, W.A. LaMarr, K.A. Foster, M.H. Barnes, D.J. Skow, P.T. Lyden, L.M. Kustigian, C. Zhi, N.C. Brown, E. George, G.E. Wright, and T.L. Bowlin Antibacterial activity and mechanism of action of a novel Anilinouracil-Fluoroquinolone hybrid compound Chemotherapy 51 2007 119 127 (Pubitemid 46047696)
31. V.M. D'Costa, E. Griffiths, and G.D. Wright Expanding the soil antibiotic resistome: exploring environmental diversity Curr. Opin. Microbiol. 10 2007 481 489 (Pubitemid 350052688)
32. D.I. Andersons, and D. Hughes Antibiotic resistance and its cost: is it possible to reverse resistance? Nat. Rev. Microbiol. 8 2010 260 271
33. A. Achari, D.O. Somers, J.N. Champness, P.K. Bryant, J. Rosemond, and D.K. Stammers Crystal structure of the anti-bacterial sulfonamide drug target dihydropteroate synthase Nat. Struct. Biol. 4 1997 490 497 (Pubitemid 27263603)
34. E.M. Scholar, and W.B. Pratt The Antimicrobial Drugs second ed. 2000 Oxford University Press New York, NY
35. H. Laue, T. Valensise, A. Seguin, S. Lociuro, K. Islam, and S. Hawser In vitro bactericidal activity of iclaprim in human plasma Antimicrob. Agents Chemother. 53 2009 4542 4544
36. U.A. Ochsner, C.L. Young, K.C. Stone, F.B. Dean, N. Janjic, and I.A. Critchley Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase Antimicrob. Agents Chemother. 49 2005 4253 4262 (Pubitemid 41400972)
37. S. Kirillov, L.A. Vitali, B.P. Goldstein, F. Monti, Y. Semenkov, V. Makhno, S. Ripa, C.L. Pon, and C.O. Gualerzi Purpuromycin: an antibiotic inhibiting tRNA aminoacylation RNA 3 1997 905 913 (Pubitemid 27332740)
38. G. Dinos, D.N. Wilson, Y. Teraoka, W. Szaflarski, P. Fucini, D. Kalpaxis, and K.H. Nierhaus Dissecting the ribosomal inhibition mechanisms of edeine and pactamycin: the universally conserved residues G693 and C795 regulate P-site RNA binding Mol. Cell 13 2004 113 124 (Pubitemid 38117120)
39. F. Schluenzen, C. Takemoto, D.N. Wilson, T. Kaminishi, J.M. Harms, K. Hanawa-Suetsugu, W. Szaflarski, M. Kawazoe, M. Shirouzu, K.H. Nierhaus, S. Yokoyama, and P. Fucini The antibiotic kasugamycin mimics mRNA nucleotides to destabilize tRNA binding and inhibit canonical translation initiation Nat. Struct. Mol. Biol. 13 2006 871 878 (Pubitemid 44527368)
40. L. Belova, T. Tenson, L. Xiong, P.M. McNicholas, and A.S. Mankin A novel site of antibiotic action in the ribosome: interaction of evernimicin with the large ribosomal subunit Proc. Natl. Acad. Sci. USA 98 2001 3726 3731 (Pubitemid 32249839)
41. C. Grigoriadou, S. Marzi, S. Kirillov, C.O. Gualerzi, and B.S. Cooperman A quantitative kinetic scheme for 70S translation initiation complex formation J. Mol. Biol. 373 2007 562 572 (Pubitemid 47488388)
42. A. Parmeggiani, and P. Nissen Elongation factor Tu-targeted antibiotics: four different structures, two mechanisms of action FEBS Lett. 580 2006 4576 4581 (Pubitemid 44189384)
43. S.C. Blanchard, R.L. Gonzalez, H.D. Kim, S. Chu, and J.D. Puglisi TRNA selection and kinetic proofreading in translation Nat. Struct. Mol. Biol. 11 2004 1008 1014 (Pubitemid 39315306)
44. D.N. Wilson, F. Schluenzen, J.M. Harms, A.L. Starosta, S.R. Connell, and P. Fucini The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning Proc. Natl. Acad. Sci. USA 105 2008 13339 13344
45. K. Fredrick, and H.F. Noller Catalysis of ribosomal translocation by sparsomycin Science 300 2003 1159 1162 (Pubitemid 36583103)
46. J.L. Hansen, P.B. Moore, and T.A. Steitz Structures of five antibiotics bound at the peptidyl transferase center of the large ribosomal subunit J. Mol. Biol. 330 2003 1061 1075 (Pubitemid 36818903)
47. M.D. Guerrero, and J. Modolell Hygromycin A, a novel inhibitor of ribosomal peptidyltransferase Eur. J. Biochem. 107 1980 409 414
48. J. Spizek, J. Novotna, and T. Rezanka Lincosamides: chemical structure, biosynthesis, mechanism of action, resistance, and applications Adv. Appl. Microbiol. 56 2004 121 154
49. M. Bagley, J. Dale, E. Merritt, and X. Xiong Thiopeptide antibiotics Chem. Rev. 105 2005 685 714 (Pubitemid 40351637)
50. F. Peske, A. Savelsbergh, V.I. Katunin, M.V. Rodnina, and W. Wintermeyer Conformational changes of the small ribosomal subunit during elongation factor G-dependent tRNA-mRNA translocation J. Mol. Biol. 343 2004 1183 1194 (Pubitemid 39387819)
51. H. Seo, S. Abedin, D. Kamp, D.N. Wilson, K.H. Nierhaus, and B.S. Cooperman EF-G-dependent GTPase on the ribosome. Conformational change and fusidic acid inhibition Biochemistry 45 2006 2504 2514
52. F. Schlünzen, J.M. Harms, F. Franceschi, H.A. Hansen, H. Bartels, R. Zarivach, and A. Yonath Structural basis for the antibiotic activity of ketolides and azalides Structure (Camb.) 11 2003 329 338 (Pubitemid 36287695)
53. A.L. Starosta, H. Qin, A. Mikolajka, G.Y. Leung, K. Schwinghammer, K.C. Nicolaou, D.Y. Chen, B.S. Cooperman, and D.N. Wilson Identification of distinct thiopeptide-antibiotic precursor lead compounds using translation machinery assays Chem. Biol. 16 2009 1087 1096
54. C. Zhang, D.L. Zink, M. Ushio, B. Burgess, R. Onishi, P. Masurekar, J.F. Barrett, and S.B. Singh Isolation, structure, and antibacterial activity of thiazomycin A, a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosa Bioorg. Med. Chem. 16 2008 8818 8823
55. C. Zhang, J. Occi, P. Masurekar, J.F. Barrett, D.L. Zink, S. Smith, R. Onishi, S. Ha, O. Salazar, O. Genilloud, A. Basilio, F. Vicente, C. Gill, E.J. Hickey, K. Dorso, M. Motyl, and S.B. Singh Isolation, structure, and antibacterial activity of philipimycin, a thiazolyl peptide discovered from Actinoplanes philippinensis MA7347 J. Am. Chem. Soc. 130 2008 12102 12110
56. J.I. Montgomery, P.L. Toogood, K.M. Hutchings, J. Liu, L. Narasimhan, T. Braden, M.R. Dermyer, A.D. Kulynych, Y.D. Smith, J.S. Warmus, and C. Taylor Discovery and SAR of benzyl phenyl ethers as inhibitors of bacterial phenylalanyl-tRNA synthetase Bioorg. Med. Chem. Lett. 19 2009 665 669
57. K. Bodewits, C.R. Raetz, J.R. Govan, and D.J. Campopiano Antimicrobial activity of CHIR-090, an inhibitor of lipopolysaccharide biosynthesis, against the Burkholderia cepacia complex Antimicrob. Agents Chemother. 54 2010 3531 3533
58. N. Srinivas, P. Jetter, B.J. Ueberbacher, M. Werneburg, K. Zerbe, J. Steinmann, B. Van der Meijden, F. Bernardini, A. Lederer, R.L. Dias, P.E. Misson, H. Henze, J. Zumbrunn, F.O. Gombert, D. Obrecht, P. Hunziker, S. Schauer, U. Ziegler, A. Käch, L. Eberl, K. Riedel, S.J. DeMarco, and J.A. Robinson Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa Science 327 2010 1010 1013
59. N. Ooi, K. Miller, J. Hobbs, W. Rhys-Williams, W. Love, and I. Chopra XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity J. Antimicrob. Chemother. 64 2009 735 740
60. K. Andries, P. Verhasselt, J. Guillemont, H.W. Göhlmann, J.M. Neefs, H. Winkler, J. Van Gestel, P. Timmerman, M. Zhu, E. Lee, P. Williams, D. de Chaffoy, E. Huitric, S. Hoffner, E. Cambau, C. Truffot-Pernot, N. Lounis, and V. Jarlier A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 307 2005 223 237
61. B.D. Bax, P.F. Chan, D.S. Eggleston, A. Fosberry, D.R. Gentry, F. Gorrec, I. Giordano, M.M. Hann, A. Hennessy, M. Hibbs, J. Huang, E. Jones, J. Jones, K.K. Brown, C.J. Lewis, E.W. May, M.R. Saunders, O. Singh, C.E. Spitzfaden, C. Shen, A. Shillings, A.J. Theobald, A. Wohlkonig, N.D. Pearson, and M.N. Gwynn Type IIA topoisomerase inhibition by a new class of antibacterial agents Nature 466 2010 935 940
62. A.A. Miller, G.L. Bundy, J.E. Mott, J.E. Skepner, T.P. Boyle, D.W. Harris, A.E. Hromockyj, K.R. Marotti, G.E. Zurenko, J.B. Munzner, M.T. Sweeney, G.F. Bammert, J.C. Hamel, C.W. Ford, W.Z. Zhong, D.R. Graber, G.E. Martin, F. Han, L.A. Dolak, E.P. Seest, J.C. Ruble, G.M. Kamilar, J.R. Palmer, L.S. Banitt, A.R. Hurd, and M.R. Barbachyn Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors Antimicrob. Agents Chemother. 52 2008 2806 2812
63. A. Tupin, M. Gualtieri, J.-P. Leonetti, and K. Brodolin The transcription inhibitor lipiarmycin blocks DNA fitting into the RNA polymerase catalytic site EMBO J. 29 2010 2527 2537
64. J. Mukhopadhyay, K. Das, S. Ismail, D. Koppstein, M. Jang, B. Hudson, S. Sarafianos, S. Tuske, J. Patel, R. Jansen, H. Irschik, E. Arnold, and R.H. Ebright The RNA polymerase "switch region" is a target for inhibitors Cell 135 2008 295 307
65. J.A. Karlowsky, N.M. Laing, T. Baudry, N. Kaplan, D. Vaughan, D.J. Hoban, and G.G. Zhanel In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis Antimicrob. Agents Chemother. 5 2007 1580 1581 (Pubitemid 46586859)
66. J. Wang, S.M. Soisson, K. Young, W. Shoop, S. Kodali, A. Galgoci, R. Painter, G. Parthasarathy, Y.S. Tang, R. Cummings, S. Ha, K. Dorso, M. Motyl, H. Jayasuriya, J. Ondeyka, K. Herath, C. Zhang, L. Hernandez, J. Allocco, A. Basilio, J.R. Tormo, O. Genilloud, F. Vicente, F. Pelaez, L. Colwell, S.H. Lee, B. Michael, T. Felcetto, C. Gill, L.L. Silver, J.D. Hermes, K. Bartizal, J. Barrett, D. Schmatz, J.W. Becker, D. Cully, and S.B. Singh Platensimycin is a selective FabF inhibitor with potent antibiotic properties Nature 441 2006 358 361 (Pubitemid 44050201)
67. J. Wang, S. Kodali, S.H. Lee, A. Galgoci, R. Painter, K. Dorso, F. Racine, M. Motyl, L. Hernandez, E. Tinney, S.L. Colletti, K. Herath, R. Cummings, O. Salazar, I. González, A. Basilio, F. Vicente, O. Genilloud, F. Pelaez, H. Jayasuriya, K. Young, D.F. Cully, and S.B. Singh Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties Proc. Natl. Acad. Sci. USA 104 2007 7612 7616 (Pubitemid 47185954)
68. J.R. Miller, S. Dunham, I. Mochalkin, C. Banotai, M. Bowman, S. Buist, B. Dunkle, D. Hanna, H.J. Harwood, M.D. Huband, A. Karnovsky, M. Kuhn, C. Limberakis, J.Y. Liu, S. Mehrens, W.T. Mueller, L. Narasimhan, A. Ogden, J. Ohren, J.V. Prasad, J.A. Shelly, L. Skerlos, M. Sulavik, V.H. Thomas, S. VanderRoest, L. Wang, Z. Wang, A. Whitton, T. Zhu, and C.K. Stover A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore Proc. Natl. Acad. Sci. USA 106 2009 1737 1742
69. J. Riedlinger, A. Reicke, H. Zähner, B. Krismer, A.T. Bull, L.A. Maldonado, A.C. Ward, M. Goodfellow, B. Bister, D. Bischoff, R.D. Süssmuth, and H.P. Fiedler Abyssomicins, inhibitors of the para-aminobenzoic acid pathway produced by the marine Verrucosispora strain AB-18-032 J. Antibiot. 57 2004 271 279 (Pubitemid 38594465)
70. D.J. Haydon, N.R. Stokes, R. Ure, G. Galbraith, J.M. Bennett, D.R. Brown, P.J. Baker, V.V. Barynin, D.W. Rice, S.E. Sedelnikova, J.R. Heal, J.M. Sheridan, S.T. Aiwale, P.K. Chauhan, A. Srivastava, A. Taneja, I. Collins, J. Errington, and L.G. Czaplewski An inhibitor of FtsZ with potent and selective anti-staphylococcal activity Science 321 2008 1673 1675
71. D.A. Rasko, C.G. Moreira, R. Li de, N.C. Reading, J.M. Ritchie, M.K. Waldor, N. Williams, R. Taussig, S. Wei, M. Roth, D.T. Hughes, J.F. Huntley, M.W. Fina, J.R. Falck, and V. Sperandio Targeting QseC signaling and virulence for antibiotic development Science 321 2008 1078 1080
72. J. Kirstein, A. Hoffmann, H. Lilie, R. Schmidt, H. Rübsamen- Waigmann, H. Brötz-Oesterhelt, A. Mogk, and K. Turgay The antibiotic ADEP reprogrammes ClpP, switching it from a regulated to an uncontrolled protease EMBO Mol. Med. 1 2009 37 49
73. J. Mulhbacher, E. Brouillette, M. Allard, L.C. Fortier, F. Malouin, and D.A. Lafontaine Novel riboswitch ligand analogs as selective inhibitors of guanine-related metabolic pathways PLoS Pathog. 6 2010 e1000865